Clofazimine induced pigmentation in leprosy patches

Chavhan, Samiksha Deepak; Jawade, Sugat

doi:10.11604/pamj.2022.42.14.34956

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On dermoscopy, it shows yellow to white globules on a black background and honeycomb patterns [6]. Clofazimine-induced pigmentation resolves after months to years upon discontinuation [7].…”

Section: Localized and Diffuse Pigmentationmentioning

confidence: 99%

Drug-Induced Pigmentation

Preclaro¹

2023

Pigmentation Disorders - Etiology and Recent Advances in Treatments

View full text Add to dashboard Cite

Drug-induced pigmentation occurs in up to 20% of acquired pigmentary disorders of the skin. Association of its occurrence was reported in certain drugs, including alkylating/cytotoxic agents, analgesics, antiarrhythmics, anticoagulants, antiepileptics, antimalarials, antimicrobials, antiretrovirals, metals, prostaglandin analogs, and psychotropic agents, among others. Proposed mechanisms include (1) accumulation of melanin, (2) accumulation of drug, (3) generation of new pigment, and (4) deposition of iron. Though difficult to confirm the drug association, the history, with emphasis on currently used drugs, and clinical examination may guide practitioners to an accurate diagnosis. Treatment options include cessation of the drug, adequate sun protection, and non-ablative pigment lasers.

show abstract

Section: Localized and Diffuse Pigmentationmentioning

confidence: 99%

Drug-Induced Pigmentation

Preclaro¹

2023

Pigmentation Disorders - Etiology and Recent Advances in Treatments

View full text Add to dashboard Cite

show abstract

“… 2 , 6 Clofazimine can cause skin discoloration, which tends to localize in plaques and nodules on the face and extremities leading to stigmatizing aesthetic abnormalities. 15 , 16 Clofazimine-induced pigmentation takes months to years to resolve after discontinuation of the drug ( Figure 1 ). In addition, daily rifampin may cause serious drug–drug interactions reduced glucocorticoid efficacy, hepatotoxicity, acute interstitial nephritis, and other systemic side effects.…”

Section: Introductionmentioning

confidence: 99%

Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States

Franco‐Paredes

Garcia-Creighton

Henao‐Martínez

et al. 2022

Therapeutic Advances in Infection

View full text Add to dashboard Cite

The World Health Organization (WHO) recommends multidrug therapy (MDT) for the treatment of paucibacillary and multibacillary forms of leprosy, also known as Hansen’s disease (HD). MDT combinations of dapsone, rifampin, and clofazimine have reduced the prevalence of the disease but are not without adverse effects impacting regimen adherence. Hence, an urgent need exists to consider alternative MDT regimens with an improved safety profile that promotes treatment adherence. Herein, we described a case series of 10 patients with HD (nine patients with multibacillary leprosy and one with pure neural leprosy) treated with monthly rifampin, moxifloxacin, and minocycline (RMM). The United States National Hansen’s Disease Program (NHDP) diagnosed and treated patients across US institutions. All patients received a regimen of 12–24 months of RMM. We reviewed the clinical outcomes, adherence, rate of completion, and adverse events of patients treated with monthly RMM from January 2019 to August 2022. Nine patients had multibacillary leprosy, with some having type-2 reactions. One patient had pure neural leprosy with a reversal reaction. In this case series, we identified that all patients completed the RMM regimen without treatment interruptions. None of the patients experienced any skin hyperpigmentation or any significant side effects. All patients tolerated the monthly RMM regimen with rapid improvement of skin lesions and without logistic hurdles. Based on previous clinical evidence and the results of this case series, the NHDP and other programs should consider the RMM regimen as first-line therapy.

show abstract

Drug-Induced Pigmentation: A Review

Tisack,

Mohammad

2024

Drugs

View full text Add to dashboard Cite

Clofazimine induced pigmentation in leprosy patches

Cited by 3 publications

References 0 publications

Drug-Induced Pigmentation

Drug-Induced Pigmentation

Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States

Drug-Induced Pigmentation: A Review

Contact Info

Product

Resources

About